Dr. Mark Lambrecht

Global Head of Health & Life Sciences Advisory at SAS. Analytical innovation for pharmaceutical manufacturers, health care payers, providers and governments.

Loud and Clear: Better Data - Not Bigger Models - are needed in health care

It’s the biology, stupid

The SaaSpocalypse That Isn't

Of Gene-Edited Cows and Factory Robots

Technologies looking for a problem to solve

The Use Of AI & Agents: Modernization Of The Clinical Data Flow - Tensai

Agentic AI in health care and life sciences: autonomy, accountability and the architecture of trust - SAS Voices

SAS is ready to support customers exploring Bayesian methodologies in clinical trials following FDA announcement

From quantum to clinic: AI reshapes clinical trials | Article | European Pharmaceutical Review

The experimentation phase of agentic AI is over

Modernizing clinical analysis and submission with SAS® Clinical Acceleration

Explore other Linktrees

SAG Awards@sagawards

zoltancomedy@zoltancomedy

Tiara Willis@thetiarawillis

Lolife@lolife.wav

royelotis@royelotis

Sabrina Carpenter@sabrinacarpenter

Are We Still Friends@awsfpod

Alyson Stoner@alysonstoner

Katie Lynn@katielynnteaches

Chelsea Handler@chelseahandler

About this account

mark_lambrecht

To help keep our community authentic, we're showing information about accounts on Linktree.

JoinedMay 2026

Mark is the Global Head of Health and Life Sciences Advisory at SAS. He and his team work at the intersection of research, information science and analytical cloud technology, solving advanced analytical and AI challenges for hospitals, pharmaceutical manufacturers and other healthcare organisations. Prior to joining SAS, he worked in the pharmaceutical industry and earned a master's degree and a PhD in Applied Bioscience Engineering (Cell and Gene Technology) from the University of Leuven (Belgium). He conducted postdoctoral research at Stanford University (USA).